Celularity Inc
For the period ended Dec 31, 2025. Filed Apr 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 30, 2026
CELU$0.71-6.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on the signature page)
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Robert J. Hariri | Chief Executive Officer and Chairman of the Board of Directors (Principal Executive Officer) | April 30, 2026 |
| Robert J. Hariri, M.D., Ph.D. | ||
| /s/ John M. Sprague | Chief Financial Officer (Principal Financial and Accounting Officer) | April 30, 2026 |
| John M. Sprague | ||
| /s/ Vincent LeVien | Director | April 30, 2026 |
| Vincent LeVien | ||
| /s/ Diane Parks | Director | April 30, 2026 |
| Diane Parks | ||
| /s/ Geoffrey Ling M.D. | Director | April 30, 2026 |
| Geoffrey Ling, M.D. | ||
| /s/ Peter Diamandis | Director | April 30, 2026 |
| Peter Diamandis, M.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.